SuperworthCVRx EPS CVRX
Diluted earnings per share by quarter and over the last twelve months, from 2020.
- Last 12 months, to Jun 30, 2026
- −$1.98
- Latest quarter, Q2 FY26
- −$0.53
- Fiscal year 2025
- −$2.05
CVRx's earnings per share was −$1.98 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.53.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$2.05 | n/a |
| FY2024 | −$2.69 | n/a |
| FY2023 | −$1.98 | n/a |
| FY2022 | −$2.02 | n/a |
| FY2021 | −$73.22 | n/a |
| FY2020 | −$37.32 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.53 | n/a | −$1.98 | |
| Q1 FY26 | −$0.50 | n/a | −$2.02 | |
| Q4 FY25 | −$0.46 | n/a | −$2.05 | |
| Q3 FY25 | −$0.49 | n/a | −$2.02 | |
| Q2 FY25 | −$0.57 | n/a | −$2.10 | |
| Q1 FY25 | −$0.53 | n/a | −$2.18 | |
| Q4 FY24 | −$0.43 | n/a | −$2.69 | |
| Q3 FY24 | −$0.57 | n/a | −$2.70 | |
| Q2 FY24 | −$0.65 | n/a | −$2.56 | |
| Q1 FY24 | −$1.04 | n/a | −$2.47 | |
| Q4 FY23 | −$0.44 | n/a | −$1.98 | |
| Q3 FY23 | −$0.43 | n/a | −$2.05 |
Against its peers
Companies in Medical - Instruments & Supplies nearest CVRx's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| CVRXCVRx | −$1.98 | |
| NEPHNephros | $0.16 | +33% a year |
| APTAlpha Pro Tech | $0.41 | +24% a year |
| KEQUKewaunee Scientific | $2.76 | −33% a year |
| PDEXPro DEX | $4.11 | +52% a year |
| UTMDUtah Medical Products | $3.28 | −12% a year |
| INFUInfuSystem | $0.41 | +78% a year |
| Peer median | $1.58 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on CVRx
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.